Previous studies have revealed that the CD4+/CD8+ ratio for lymphocytes of peripheral blood and peritoneal fluid seems helpful in monitoring disease progression in ovarian or breast cancer patients [21], [22]. The gene discussed is CD8A; the disease is breast carcinoma.